MREO 4.62 (+1.32%)
US5894921072BiotechnologyBiotechnology

Mereo BioPharma Group (MREO) Stock Highlights

4.62 | +1.32%
2024-10-21 03:17:19
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Statistics

Range Today
4.49 4.64
Volume Today 405.1K
Range 1 Year
1.59 5.02
Volume 1 Year 294.8M
Range 3 Year
0.3 5.02
Volume 3 Year 1.08B
Range 10 Year
0.3 8.48
Volume 10 Year 1.58B

Highlights

Market Capitalization 710.8M (small)
Floating Shares 485.07M
Current Price 4.62
Price To Earnings -18.12
Price To Revenue 3.47K
Price To Book 9.02
Earnings Per Share -0.25
Payout Ratio 0%

Performance

Latest +1.32%
1 Month +12.14%
3 Months +17.86%
6 Months +80.47%
1 Year +155.25%
3 Years +111.93%
5 Years +32.76%
10 Years -4.15%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.